




THE NOVELTY STUDY

Identifying new dimensions in respiratory disease

NOVELTYstudy.com

A large, global, prospective, longitudinal, observational study characterising patients with obstructive lung disease¹



Eligibility:

Proportion of adult asthma/COPD patients eligible for:




Randomised Clinical Trials 5%^{3,4}




NOVELTY ≥95%
All patients aged ≥12 years (in most countries, aged ≥18 years), not participating in an interventional trial

Global (~12,000 patients across 19 countries):



Diverse population: mixed phenotypes and endotypes



Study Design


Baseline and annual assessments in the clinic, plus 3-monthly assessments captured remotely

2-year extension study at selected sites




Clinical Assessment

To characterise patients by their clinical profile (phenotype)



Biomarker Assessment

To characterise patients by disease mechanism (endotype)



A phenotype may be comprised of several endotypes

The NOVELTY Study

A platform to support the development of personalised healthcare  to deliver the right treatment to the right patient at the right time

References

1. Reddel HK et al. ERJ Open Res 2019;5:00036–2018
2. Bateman ED et al. Lancet Respir Med 2015;3:719-728
3. Travers J et al. Respir Med 2007;101:1313-1320
4. Travers J et al. Thorax 2007;62:219-223